SCHEMBL8737941

SCHEMBL8737941

COc1ccc(C(N)=O)cc1Nc1nc(-c2sc(C)nc2C)cs1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.71
KMT2A Q03164 10/20 0.71
MAPT P10636 9/20 0.71
GAA P10253 5/20 0.71
MAPK1 P28482 1/20 0.71
NPSR1 Q6W5P4 1/20 0.71
OPRM1 P35372 3/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
ALDH1A1 P00352 6/20 0.61
TDP1 Q9NUW8 2/20 0.61
HSD17B10 Q99714 1/20 0.61
CFTR P13569 4/20 0.59
SMN1; SMN2 Q16637 5/20 0.58
LMNA P02545 4/20 0.58
HTT P42858 4/20 0.58
KDM4E B2RXH2 4/20 0.58
HPGD P15428 3/20 0.58
CYP3A4 P08684 2/20 0.58
CYP2C9 P11712 2/20 0.58
CYP2C19 P33261 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL6114509 0.99 MEN1 (0.70) MEN1KMT2AMAPTGAAMAPK1
SCHEMBL6113878 0.92 OPRM1 (0.71) MEN1KMT2AMAPTGAAMAPK1
SCHEMBL8738343 0.92 MEN1 (0.73) MEN1KMT2AMAPTGAAMAPK1
Bromide SCHEMBL6114277 0.91 MEN1 (0.71) MEN1KMT2AMAPTGAAMAPK1
SCHEMBL6114393 0.89 MEN1 (0.56) MEN1KMT2AMAPTGAAMAPK1
SCHEMBL8738028 0.89 MEN1 (0.56) MEN1KMT2AMAPTGAAMAPK1
SCHEMBL8739106 0.89 MAPT (0.67) MEN1KMT2AMAPTGAAMAPK1
SCHEMBL8738025 0.89 MMP9 (0.73) MEN1KMT2AMAPTGAANPSR1
Bromide SCHEMBL6113988 0.89 MEN1 (0.56) MEN1KMT2AMAPTGAAMAPK1
SCHEMBL6114137 0.89 MEN1 (0.56) MEN1KMT2AMAPTGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed
WO-2012068209-A2 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, MMP2 MEN1 2298/4885KMT2A 2435/4885MAPT 3531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.